My first response when thinking about the ultimate growth stock to buy with $1,000 right now was to go with a high-flying AI stock. But the more I deliberated, the less comfortable I was choosing one of those stocks.Don't get me wrong. I like (and own) several great AI stocks. However, I could easily name downsides to all of them. So which stock do I think is the ultimate pick to buy with $1,000 right now? After careful consideration, my answer is... Vertex Pharmaceuticals (VRTX 0.78%).Accentuating the posi ...

Vertex Pharmaceuticals (VRTX -0.96%) has wowed investors in recent times as it's expanded beyond its specialty area of cystic fibrosis (CF) treatment. The company launched Casgevy, a one-time curative gene editing treatment for blood disorders sickle cell disease and beta thalassemia. And Vertex recently reported positive data from trials of its pain management candidate and aims to file for regulatory review this year.All of this is great and could result in billions of dollars in revenue. But Vertex also ...

Vertex Pharmaceuticals (VRTX -0.96%) is the global leader in cystic fibrosis (CF) treatment, and that specialty has helped it generate billions of dollars in earnings. But the company has also spent the past few years developing candidates outside of this treatment area, in an effort to become a well-diversified biotech player.In fact, Vertex's next product to market may be one that could treat one of the most common problems around -- pain -- and generate blockbuster revenue. The company aims to submit tha ...

I've been a big fan of Vertex Pharmaceuticals (VRTX 0.44%), and the biotech stock has made me a lot of money throughout the years. Vertex continues to enjoy a virtual monopoly in treating cystic fibrosis (CF) but it's advancing multiple promising programs in its pipeline.However, investors who watch valuation metrics closely might have noticed something concerning about Vertex: Its shares trade at a price-to-sales (P/S) ratio of over 11x. Is Vertex stock too expensive right now?Relatively speakingLet's ackn ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts (State or other jurisdiction of i ...

Vertex Pharmaceuticals (VRTX) and partner CRISPR Therapeutics (CRSP) announced that the European Commission has granted conditional marketing approval to their one-shot gene therapy Casgevy for treating two debilitating blood disorders, sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).Casgevy is approved for patients 12 years and older with severe SCD characterized by recurrent vaso-occlusive crises (VOCs) or TDT, for whom hematopoietic stem cell (HSC) transplantation is appropriat ...

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has granted conditional marketing authorization to CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy. CASGEVY is approved for the treatment of patients who are 12 years of age and older with severe sickle cell disease (SCD) characterized by recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT), for whom hematopoietic stem cel ...

Vertex Pharmaceuticals (VRTX -0.04%) has been one of the hottest growth stocks to own within the healthcare industry. The company has a dominant cystic fibrosis (CF) business, and it has been expanding into other areas as well. Last year, Vertex's shares rose by just under 41%, easily outperforming the S&P 500, which increased by a still-respectable 24%.Can this biotech continue rallying after posting its latest earnings numbers, or has it become too expensive?Vertex's growth rate is slowing downOn Feb. 5, ...

Vertex Pharmaceuticals Incorporated (VRTX) reported fourth-quarter 2023 adjusted earnings per share of $4.20, which beat the Zacks Consensus Estimate of $4.10. Earnings increased 12% year over year. Strong cystic fibrosis (“CF”) product revenues led to higher earnings in the reported quarter.Revenues of $2.52 billion surpassed the Zacks Consensus Estimate of $2.49 billion. Revenues solely comprised CF product revenues. Total product revenues rose 9.3% year over year, primarily driven by higher sales of Trik ...

Biotech giant Vertex Pharmaceuticals (VRTX 0.99%) ended 2023 with an important regulatory approval. The company's gene-editing therapy for a duo of blood-related disorders, Casgevy, earned the nod in several countries. This development capped off another excellent year for the drugmaker, one during which -- as usual -- it crushed the market.However, at least on the clinical front, Vertex isn't exactly starting 2024 with a bang. The company recently released positive but somewhat disappointing data from a ph ...